Active mouse tPA, recombinant

1. Roelofs JJ, Rouschop KM, Leemans JC et-al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J. Am. Soc. Nephrol. 2006;17 (1): 131-40. doi:10.1681/ASN.2005010089 – Pubmed citation

2. Hu K, Yang J, Tanaka S et-al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J. Biol. Chem. 2006;281 (4): 2120-7. doi:10.1074/jbc.M504988200 – Pubmed citation

3. Merchan JR, Tang J, Hu G et-al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J. Natl. Cancer Inst. 2006;98 (11): 756-64. doi:10.1093/jnci/djj208 – Pubmed citation

4. Polavarapu R, Gongora MC, Yi H et-al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007;109 (8): 3270-8. doi:10.1182/blood-2006-08-043125 – Free text at pubmed – Pubmed citation

5. Zhang X, Polavarapu R, She H et-al. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation. Am. J. Pathol. 2007;171 (4): 1281-90. doi:10.2353/ajpath.2007.070472 – Free text at pubmed – Pubmed citation

6. An J, Zhang C, Polavarapu R et-al. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood. 2008;112 (7): 2787-94. doi:10.1182/blood-2008-02-141630 – Free text at pubmed – Pubmed citation

7. Lund IK, Jögi A, Rønø B et-al. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J. Biol. Chem. 2008;283 (47): 32506-15. doi:10.1074/jbc.M801924200 – Pubmed citation

8. Roelofs JJ, Rouschop KM, Teske GJ et-al. Endogenous tissue-type plasminogen activator is protective during ascending urinary tract infection. Nephrol. Dial. Transplant. 2009;24 (3): 801-8. doi:10.1093/ndt/gfn562 – Pubmed citation

9. Ilkovitch D, Lopez DM. Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood. 2009;113 (19): 4729-39. doi:10.1182/blood-2008-08-176438 – Free text at pubmed – Pubmed citation

10. Roussel BD, Macrez R, Jullienne A et-al. Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain. 2009;132 (Pt): 2219-30. doi:10.1093/brain/awp162 – Free text at pubmed – Pubmed citation

11. Wu F, Wu J, Nicholson AD et-al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J. Neurosci. 2012;32 (29): 9848-58. doi:10.1523/JNEUROSCI.1241-12.2012 – Free text at pubmed – Pubmed citation

12. Li J, Yu L, Gu X et-al. Tissue plasminogen activator regulates Purkinje neuron development and survival. Proc. Natl. Acad. Sci. U.S.A. 2013;110 (26): E2410-9. doi:10.1073/pnas.1305010110 – Free text at pubmed – Pubmed citation

13. Sanderson-smith ML, Zhang Y, Ly D et-al. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog. 2013;9 (7): e1003469. doi:10.1371/journal.ppat.1003469 – Free text at pubmed – Pubmed citation

14. Valapala M, Maji S, Borejdo J et-al. Cell Surface Translocation of Annexin A2 Facilitates Glutamate-induced Extracellular Proteolysis. J. Biol. Chem. 2014;289 (23): 15915-15926. doi:10.1074/jbc.M113.511550 – Free text at pubmed – Pubmed citation

15. Chen, Chia-Chien, Philip Chu, and Joshua C. Brumberg. ‘Experience-Dependent Regulation Of Tissue-Type Plasminogen Activator In The Mouse Barrel Cortex’. Neuroscience Letters (2015): n. pag. Web. 5 June 2015. Link to article

16. Wu F, Torre E, Cuellar-giraldo D, et al. Tissue-type plasminogen activator triggers the synaptic vesicle cycle in cerebral cortical neurons. J Cereb Blood Flow Metab. 2015. Link to article

17. Lewandowski SA, Nilsson I, Fredriksson L, et al. Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol. 2016;131(3):453-64.

18. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14(7):731-7. Link to article

19. Jeanneret V, Wu F, Merino P, et al. Tissue-type Plasminogen Activator (tPA) Modulates the Postsynaptic Response of Cerebral Cortical Neurons to the Presynaptic Release of Glutamate. Front Mol Neurosci. 2016;9:121. Link to article.

20. Andersen LM, Wind T, Hansen HD, Andreasen PA. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. Biochem J. 2008;412(3):447-57. Link to article

21. Rzeczycki, P. The Role of Macrophages in the Sequestration of Drug and Formation of Insoluble Drug Aggregates. Link to article

22. García-vázquez FA, Soriano-Úbeda C, Laguna-barraza R, et al. Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of invitro but not of invivo fertilisation in the mouse. Reprod Fertil Dev. 2018; Link to article

23. Diaz A, Jeanneret V, Merino P, Mccann P, Yepes M. Tissue-type plasminogen activator regulates p35-mediated Cdk5 activation in the postsynaptic terminal. J Cell Sci. 2019;132(5). Link to article